Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) CFO William J. Peters sold 19,801 shares of Amphastar Pharmaceuticals stock in a transaction dated Tuesday, March 13th. The stock was sold at an average price of $20.10, for a total transaction of $398,000.10. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
Shares of NASDAQ AMPH opened at $19.01 on Friday. The stock has a market cap of $887.15, a PE ratio of 50.03, a PEG ratio of 1.36 and a beta of 1.42. Amphastar Pharmaceuticals Inc has a 12 month low of $13.15 and a 12 month high of $20.45. The company has a quick ratio of 1.85, a current ratio of 2.79 and a debt-to-equity ratio of 0.12.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings results on Monday, March 12th. The company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of $0.07 by $0.03. The business had revenue of $60.40 million during the quarter, compared to the consensus estimate of $60.62 million. Amphastar Pharmaceuticals had a net margin of 1.88% and a return on equity of 4.56%. The company’s quarterly revenue was down 4.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.01 earnings per share. research analysts predict that Amphastar Pharmaceuticals Inc will post 0.63 earnings per share for the current fiscal year.
A number of equities analysts have issued reports on AMPH shares. Zacks Investment Research cut shares of Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, December 27th. BidaskClub cut shares of Amphastar Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Tuesday, January 9th. Piper Jaffray restated a “buy” rating and set a $26.00 target price on shares of Amphastar Pharmaceuticals in a research report on Tuesday, January 30th. Needham & Company LLC restated a “buy” rating and set a $24.00 target price (up previously from $23.00) on shares of Amphastar Pharmaceuticals in a research report on Tuesday, March 13th. Finally, BMO Capital Markets restated a “market perform” rating and set a $19.00 target price (up previously from $17.00) on shares of Amphastar Pharmaceuticals in a research report on Tuesday, March 13th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $21.33.
Several hedge funds and other institutional investors have recently modified their holdings of AMPH. Millennium Management LLC grew its holdings in shares of Amphastar Pharmaceuticals by 1,746.9% during the fourth quarter. Millennium Management LLC now owns 293,672 shares of the company’s stock worth $5,650,000 after buying an additional 277,771 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Amphastar Pharmaceuticals by 17.0% during the third quarter. Dimensional Fund Advisors LP now owns 1,558,113 shares of the company’s stock worth $27,844,000 after buying an additional 226,271 shares in the last quarter. Wells Fargo & Company MN grew its holdings in shares of Amphastar Pharmaceuticals by 156.1% during the fourth quarter. Wells Fargo & Company MN now owns 176,323 shares of the company’s stock worth $3,392,000 after buying an additional 107,486 shares in the last quarter. Alliancebernstein L.P. grew its holdings in shares of Amphastar Pharmaceuticals by 148.9% during the fourth quarter. Alliancebernstein L.P. now owns 113,520 shares of the company’s stock worth $2,184,000 after buying an additional 67,920 shares in the last quarter. Finally, Argent Capital Management LLC grew its holdings in shares of Amphastar Pharmaceuticals by 102.6% during the third quarter. Argent Capital Management LLC now owns 121,275 shares of the company’s stock worth $2,167,000 after buying an additional 61,425 shares in the last quarter. Institutional investors and hedge funds own 44.46% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/08/amphastar-pharmaceuticals-inc-amph-cfo-william-j-peters-sells-19801-shares-of-stock.html.
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.